[New anti-cytokine strategy against patients with hypercytokinemia stratified by cytokine-related genetic polymorphisms].
The effects of genomic variability on susceptibility to not only hereditary diseases but also to common diseases and on the responsiveness to drugs have been demonstrated. Moreover, the effects of genetic polymorphism on the severity and outcome of critical illness which is caused by hypercytokinemia have been evaluated. We have measured cytokine blood levels in order to evaluate the severity of critical illness and efficacy of our treatment in clinical settings. We have found that hypercytokinemia in the carriers of high-risk genotype on cytokine-related polymorphisms was not responsible to the ordinary anti-cytokine therapy such as continuous hemodiafiltration using polymethyl methacrylate membrane hemofilter. Therefore, we should apply new stronger anti-cytokine strategies toward those high-risk genotype patients.